ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A, Dadiani M, Kahana-Edwin S, Itay A, Sella T, Gadot M, Cesarkas K, Farage-Barhom S, Saar EG, Eyal E, Kol N, Pavlovski A, Balint-Lahat N, Dick-Necula D, Barshack I, Kaufman B, Gal-Yam EN.
Zundelevich A, et al. Among authors: saar eg.
Breast Cancer Res. 2020 Feb 3;22(1):16. doi: 10.1186/s13058-020-1246-5.
Breast Cancer Res. 2020.
PMID: 32014063
Free PMC article.